Skip to main content
SpringerLink
Log in

Trazodone prolonged release: a guide to its use in depression

  • ADIS DRUG CLINICAL Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Once-daily prolonged-release trazodone [Triticum® OD (Europe), Oleptro™ (USA)] offers an option for the treatment of depression in adult patients. It is effective in reducing the symptoms of depression and improving the quality of sleep, and is generally well tolerated. The prolonged release of trazodone over 24 h provided by the novel once-daily trazodone formulation may reduce the risk of adverse effects (particularly daytime sedation) associated with the early high-peak trazodone plasma concentrations obtained with immediate-release formulations of the drug, and may also enhance adherence to antidepressant treatment. The prolonged-release tablets can broken in half, providing flexibility in dosing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Fagiolini A, Comandini A, Dell’Osso MC, et al. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033–49.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Haria M, Fitton A, McTavish D. Trazodone: a review of its use pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994;4(4):331–55.

    Article  CAS  PubMed  Google Scholar 

  3. Triticum OD 150 and 300 mg prolonged-release tablets: summary of product characteristics. Cruz Quebrada-Dafundo: Angelini Farmacêutica, Lda; 2014.

  4. Oleptro™ (trazodone hydrocloride tablet, extended release): US prescribing information. Gaithersburg (MD): Angelini Pharma Inc.; 2014.

  5. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007;22(7):444–7.

    Article  PubMed  Google Scholar 

  6. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;155(11):772–85.

    Article  PubMed  Google Scholar 

  7. Beasley CM Jr, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry. 1991;52(7):294–9.

    PubMed  Google Scholar 

  8. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994;14(2):99–106.

    Article  CAS  PubMed  Google Scholar 

  9. Kasper S, Olivieri L, Di Loreto G, et al. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin. 2005;21(8):1139–46.

    Article  CAS  PubMed  Google Scholar 

  10. Moon CA, Laws D, Stott PC, et al. Efficacy and tolerability of controlled-release trazodone in depression: a large multicentre study in general practice. Curr Med Res Opin. 1990;12(3):160–8.

    Article  CAS  PubMed  Google Scholar 

  11. Munizza C, Olivieri L, Di Loreto G, et al. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2006;22(9):1703–13.

    Article  CAS  PubMed  Google Scholar 

  12. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol. 1994;14(3):170–9.

    Article  CAS  PubMed  Google Scholar 

  13. Blacker R, Shanks NJ, Chapman N, et al. The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline. Psychopharmacology. 1988;95(Suppl):S18–24.

    PubMed  Google Scholar 

  14. Feighner JP, Boyer WF. Overview of USA controlled trials of trazodone in clinical depression. Psychopharmacology. 1988;95(Suppl):S50–3.

    PubMed  Google Scholar 

  15. Owens MJ, Morgan NW, Plott SJ, et al. Neurotransmittter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283(3):1305–22.

    CAS  PubMed  Google Scholar 

  16. Sheehan DV, Croft HA, Gossen ER, et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry (Edgmont). 2009;6(5):20–33.

    PubMed Central  PubMed  Google Scholar 

  17. Sheehan DV, Rozova A, Gossen ER, et al. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. Psychopharmacol Bull. 2009;42(4):5–22.

    PubMed  Google Scholar 

  18. Clayton AH, Favit A. Concerns in depression treatment: sexual dysfunction and weight gain. Prim Psychiatry. 2007;14:66–75.

    Google Scholar 

  19. Ashton AK, Jamerson BD, Weinstein W, et al. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp. 2005;66(2):96–106.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: M. Hahn, Vitos Rheingau, Eltville, Germany; S. Kasper, Department of General Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India; R. B. Shah, Department of Pharmacology, GMERS Medical College and Hospital, Gandhinagar, Gujarat, India.

Disclosure

This article was written by a salaried employee of Adis/Springer and was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the author on the basis of scientific merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Trazodone prolonged release: a guide to its use in depression. Drugs Ther Perspect 31, 137–142 (2015). https://doi.org/10.1007/s40267-015-0207-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-015-0207-z

Keywords

Search

Navigation